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Background: The clinical efficacy and safety of a mometasone furoate/formoterol fumarate
(MF/F) fixed-dose combination formulation administered via a metered-dose inhaler was
investigated in patients with moderate to very severe chronic obstructive pulmonary disease
(COPD).
Methods: Two 52-week, multicenter, double-blind, placebo-controlled trials with identical
study designs were conducted in current or ex-smokers (aged $40 years), and pooled study
results are presented herein. Subjects (n = 2251) were randomized to 26 weeks of twice-daily
treatment with MF/F 400/10 µg, MF/F 200/10 µg, MF 400 µg, F 10 µg, or placebo. After
the 26-week treatment period, placebo subjects completed the trial and 75% of subjects on
active treatment entered a 26-week safety extension. Coprimary efficacy variables were mean
changes in forced expiratory volume in one second (FEV1), area under the curve from 0 to
12 hours postdose (AUC0–12 h), and morning predose/trough FEV1 from baseline to the week
13 endpoint. Key secondary efficacy variables were St George’s Respiratory Questionnaire
scores, symptom-free nights, time-to-first exacerbation, and partly stable COPD at the week
26 endpoint.
Results: In the 26-week treatment period, significantly greater increases in FEV1 AUC0–12 h
occurred with MF/F 400/10 versus MF 400 and placebo at the week 13 and week 26 endpoints
(P # 0.032). These increases were over three-fold greater with MF/F 400/10 than with MF 400.
Also, significantly greater increases in morning predose/trough FEV1 occurred with MF/F 400/10
versus F 10 and placebo at the week 13 endpoint (P , 0.05). The increase was four-fold greater
with MF/F 400/10 than with F 10. All active treatment groups achieved minimum clinically
important differences from baseline (.4 units) in St George’s Respiratory Questionnaire
scores at week 26. Symptom-free nights increased by $14% in the MF/F 400/10, MF 400,
and F 10 groups (P # 0.033 versus placebo). The incidence of exacerbations was lower in the
MF/F groups (#33.3%) than it was in the MF, formoterol, and placebo groups ($33.8%) over
the 26-week treatment period. The incidence of adverse events was similar in the active-treated
and placebo-treated subjects across 26 weeks of treatment. Over the 1-year study period, there
were no notable differences in the incidence or types of adverse events between the MF/F 400/10
and MF/F 200/10 groups compared with the MF or formoterol groups. Differences in rates of
individual treatment-emergent adverse events were ,3% between treatment groups. Rates of
pneumonia were low (#2%) across all treatment groups.

International Journal of COPD 2012:7 73–86
© 2012 Tashkin et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article
which permits unrestricted noncommercial use, provided the original work is properly cited.

73

Dovepress

Tashkin et al

Conclusion: Patients treated with MF/F demonstrated significant improvements in lung function, health status, and exacerbation rates.
Although significant improvements were seen with both doses, a trend showing a dose-response effect was observed in the lung function
measurements.
Keywords: COPD, spirometry, exacerbation, inhaled corticosteroid, bronchodilator

Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
and progressive disease that has an enormous impact on
patient health and health care resources. In the US, COPD
affects more than 5% of the adult population and is the third
leading cause of death. Recent estimates of total economic
costs in the US are approximately $50 billion, with the
direct cost of medical care approaching $30 billion.1 COPD
is usually characterized by dyspnea and chronic productive
cough,2 airflow obstruction that is not fully reversible, and
a heightened inflammatory process in the lungs.2 Recurrent
exacerbations, a hallmark of unstable COPD, further impair
quality of life, accelerate disease progression,2 and account
for more than 70% of the economic burden (direct costs) of
COPD on the health care system.2
Recent guidelines published by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) list potential treatment goals, ie, relieving symptoms, preventing progression,
improving exercise tolerance and health status, preventing
and treating exacerbations and complications, and reducing
mortality.2 Bronchodilators (anticholinergics, β2-agonists,
and methylxanthines) relax airway smooth muscle and
improve lung emptying during tidal breathing at rest and
during exertion.3 Long-acting inhaled bronchodilators, consisting of the long-acting anticholinergic, tiotropium, and
long-acting β2-agonists (LABAs), including twice-daily
salmeterol and formoterol, are recommended as monotherapy
for patients with moderate to severe COPD,2 and have been
shown to improve lung function, decrease symptoms, and
reduce exacerbations.4–8 In clinical trials, formoterol has demonstrated a more rapid onset of bronchodilation compared
with salmeterol in patients with COPD.9
For patients with more advanced COPD who continue
to have repeated exacerbations despite maximized use of
bronchodilators, the addition of an inhaled corticosteroid is
recommended.2 Inhaled corticosteroids have been shown to
increase the forced expiratory volume in one second (FEV1)
when added to the maintenance regimen of severe COPD
patients10,11 and to reduce the severity12 and frequency of
exacerbations.11 Mometasone furoate (MF) in a dry-powder
inhaler administered at a total daily dose of 800 µg for
12 months demonstrated significant improvements compared
with placebo in lung function, time-to-first exacerbation,
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number of exacerbations, symptoms, and health status.13
However, inhaled corticosteroid monotherapy is not recommended in COPD treatment guidelines, and inhaled corticosteroids are not approved for the treatment of COPD in
the US. It is when inhaled corticosteroids are combined with
LABAs that their effects become significant.
Concomitant therapy with an inhaled corticosteroid
plus LABA is recommended for patients with moderate to severe COPD. Recent guidelines from GOLD2 and
the National Institute for Clinical Excellence14 recommend inhaled corticosteroid/LABA combination treatment for patients with FEV1 ,50% predicted, while a
threshold of ,60% predicted for use was recommended
by a joint position paper of the American Thoracic
Society/European Respiratory Society. 1 Three inhaled
corticosteroid/LABA combination products, ie, fluticasone
propionate/salmeterol,15–17 budesonide/formoterol,18,19 and
beclomethasone dipropionate/formoterol,20,21 have been
shown to improve lung function and health status in patients
with COPD and are approved by some regulatory agencies for the maintenance treatment of COPD. Mometasone
furoate/formoterol fumarate (MF/F) was recently approved
for the treatment of asthma, and two Phase III trials assessing the effect of MF/F in subjects with severe to very severe
COPD symptoms were recently completed. We present
pooled results from the two Phase III trials of MF/F in subjects with moderate to very severe COPD, which have been
published individually, and present results in more detail.
Pooling results from these two studies of identical design
improves the precision of the estimated treatment effect for
MF/F, and provides a larger safety database for evaluation.
Pooling also gives additional information on time-to-first
COPD exacerbation, given that exacerbations occur episodically and often require larger study populations and
extended follow-up times to discern treatment benefits on
exacerbation rates.

Methods
The two studies were of identical design. These randomized, placebo-controlled, double-blind, double-dummy,
multicenter Phase III trials evaluated twice-daily treatment
with MF/F 400/10, MF/F 200/10, MF 400, F 10, and placebo in adults at least 40 years of age, with moderate to
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very severe COPD. All treatments were administered via
pressurized metered-dose inhaler. Subjects were enrolled at
mutually exclusive centers across North, Central, and South
America; Europe; Africa; and Asia (131 centers in one trial
and 164 centers in the other trial). Both trials were registered
on ClinicalTrials.gov (identifier numbers NCT00383435 and
NCT00383721). A prospective statistical analysis plan for
evaluation of pooled results was completed before unblinding
of the two studies.
The studies were conducted in accordance with the
principles of Good Clinical Practice and were approved by
the appropriate institutional review boards and regulatory
agencies. All patients gave written informed consent before
enrollment. All subjects were monitored for COPD exacerbations and were provided with a COPD action plan with
immediate availability of emergency rescue medication.
Subjects were ex-smokers or current smokers with a
smoking history of $10 pack-years and had symptoms of
COPD for at least 24 months. For inclusion, subjects were
required to have a diagnosis of moderate to very severe
COPD (based on a prebronchodilator FEV1/forced vital
capacity [FVC] ratio of #70%), and post-bronchodilator
FEV1 between 25% and 60% predicted normal at the screening visit. Subjects who experienced an increase in absolute
FEV1 of $400 mL at the screening visit or prior to the
baseline visit within 30 minutes after administration of four
inhalations of albuterol (salbutamol) 360–400 µg total, or
nebulized 2.5 mg albuterol (salbutamol) were not enrolled.
Screening period
open-label run-in
(SABA/short-acting
anticholinergic FDC)

Day –14

Screening
Baseline
(randomization)

Specific exclusion criteria were current diagnosis of asthma,
oxygen dependence, significant ocular disease (eg, cataracts,
glaucoma), abnormal bone density scan, visible evidence of
oropharyngeal candidiasis, COPD exacerbation requiring
medical intervention within 4 weeks of randomization, oral
or parenteral corticosteroid use within 6 weeks of screening,
and any clinically significant medical disorder.
Screening was followed by a 2-week, open-label run-in
period, in which short-acting β2-agonist (SABA)/shortacting anticholinergic fixed-dose combination treatment was
provided for use as needed. At the baseline visit, subjects
who qualified were randomized in a 1:1:1:1:1 ratio to twicedaily treatment with MF/F 400/10 µg, MF/F 200/10 µg,
MF 400 µg, F 10 µg, or placebo for 26 weeks (treatment
period). Total doses were delivered after two inhalations
twice daily of the following actuated doses: MF/F 200/5 µg,
MF/F 100/5 µg, MF 200 µg, F 5 µg, or placebo. The number
of inhalations and the treatment schedule were identical in
each arm, for a total of four inhalations (two inhalations from
each of two separate devices) twice daily. At the end of the
treatment period, 75% of subjects in each active treatment
group were randomly selected to continue their current treatment, in a double-blind fashion, for an additional 26 weeks
(safety extension, Figure 1).

Efficacy assessments
Clinical visits occurred at screening, baseline, day 1, weeks
1, 4, 13, 26, 39, and 52, and/or end of treatment (generally

26-week
double-blind treatment period

26-week double-blind
safety extension

MF/F MDI 400/10 µg BID

MF/F MDI 400/10 µg BIDa

MF/F MDI 200/10 µg BID

MF/F MDI 200/10 µg BIDa

MF MDI 400 µg BID

MF MDI 400 µg BIDa

F MDI 10 µg BID

F MDI 10 µg BIDa

Placebo

Figure 1 Study design.
Notes: Total doses were delivered after two inhalations twice daily of the following actuated doses: MF/F 200/5 µg, MF/F 100/5 µg, MF 200 µg, F 5 µg, or placebo.
a
75% of each group were randomly selected to continue into the safety extension.
Abbreviations: BID, twice daily; F, formoterol; FDC, fixed-dose combination; MDI, metered-dose inhaler; MF, mometasone furoate; MF/F, mometasone furoate/formoterol
fumarate fixed-dose combination formulation; SABA, short-acting β2-agonist.
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defined as the last week of treatment for each subject).
Efficacy was evaluated by pulmonary function tests at all
visits, and serial spirometry was performed at baseline, on
day 1, and at weeks 1, 13, and 26. Subjects were contacted by
telephone the day before each visit and reminded of restricted
medication washout times before the visit. Study-provided
SABA metered-dose inhalers and nebulizations of 2.5 mg
albuterol (salbutamol) were to be withheld for at least 4 hours
before visits. Washout times for vaccines (eg, influenza and
hepatitis) and immunotherapy were one week and 24 hours,
respectively. Investigators attempted to use one spirometer
consistently on each subject, and the spirometer was calibrated at each visit. The investigator or qualified designee
obtained three FEV1 and three FVC measurements at each
visit that met the American Thoracic Society/European
Respiratory Society guidelines for test acceptability and
reproducibility.22 Study sites used a centralized data system
(MasterScope CT) to capture spirometry results at each visit.
Spirometry was performed approximately 12 hours after the
last dose of study medication.
Patients recorded rescue medication usage (short-acting
β2-agonist/short-acting anticholinergic), oral prednisone/
prednisolone use, number of nocturnal awakenings requiring rescue medication, peak expiratory flow measurements,
and morning and evening COPD symptom scores daily
in e-diaries. Pulmonary health status was assessed using
the St George’s Respiratory Questionnaire (SGRQ). Deteriorations of COPD symptoms were recorded as exacerbations and
classified according to severity, ie, mild (managed with increased
short-acting bronchodilator use on any two consecutive days),
moderate (required antibiotic and/or oral steroid treatment), or
severe (resulted in emergency treatment or hospitalization).
Primary and secondary endpoints were the same in both
studies: to assess the contribution of formoterol, the first
coprimary endpoint was mean FEV1 from 0 to 12 hours
postdose (AUC0–12 h) of the change from baseline to the week
13 endpoint. Comparators were MF/F 400/10 versus MF
400, MF/F 400/10 versus placebo, and F 10 versus placebo.
Baseline FEV1 was the average of the two predose/trough
FEV1 measurements (30 minutes before dosing and immediately before dosing) at the baseline visit. To assess the
contribution of MF, the second coprimary endpoint was
the mean change from baseline to the week 13 endpoint in
morning predose/trough FEV1. Comparators were MF/F
400/10 versus F 10, MF/F 400/10 versus placebo, and MF
400 versus placebo.
Key secondary efficacy outcomes included change
from baseline in SGRQ, time-to-first COPD exacerbation,
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proportion of COPD symptom-free nights, and partly stable
COPD. The SGRQ is a three-component questionnaire that
measures symptoms, activity, and social and psychological
impacts.23 Total score ranges from 0−100, with a higher
score indicating greater disease burden. A difference in total
score of 4 points, either from baseline or between treatment
groups, has been established as the minimum clinically
important difference.24 A symptom-free night was defined
as a combined score of 0 upon awakening, prior to the use
of study drug or rescue medication, across three domains,
ie, wheezing, cough, and difficulty breathing. Exacerbation
data were analyzed for the time-to-first mild, moderate, or
severe COPD exacerbation and for the time-to-first moderate
or severe COPD exacerbation, excluding mild events. The
statistical analysis plan prespecified analysis of time-to-first
mild, moderate, or severe exacerbation, whereas analysis of
time-to-first moderate or severe exacerbation was planned
after finalization of the statistical analysis plan but before
unblinding of the database. Partly stable COPD was a composite measure of the following outcomes: no use of oral
steroid rescue medication; no morning or evening COPD
weekly average symptom score greater than 2 during at least
7 of 8 weeks; no moderate or severe COPD exacerbations;
no unscheduled visits due to COPD worsening; and no study
discontinuation due to treatment failure or treatment-related
adverse event. Secondary outcomes were evaluated over the
26-week treatment period.

Safety assessments
Subjects at all centers were monitored at each visit for
treatment-emergent adverse events, vital signs, medication use, oropharyngeal changes, and forearm bruising.
Ophthalmic examinations (measurement of intraocular pressure and Lens Opacities Classification System, Version III
[LOCS III] assessments of cataracts and lens opacification),
hypothalamic-pituitary-adrenal axis assessments (24-hour
plasma cortisol, at selected centers), and bone mineral density
measurements (lumbar spine, left total femur, and femoral
neck, at selected centers), were performed at the beginning
of the trial and at week 26 and week 52.

Statistical analysis
Statistical analyses were carried out using SAS® software
(v 9.1; SAS Institute, Cary, NC). The total target sample size
for analysis of pooled results was planned for 2000 patients
(400 per treatment group). This sample size allows detection
of a difference of 0.8 L × hour between MF/F 400/10 and
MF 400 in change from baseline FEV1 AUC0–12 h at the week
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13 endpoint, with 90% power and a two-sided alpha level of
5% significance, assuming a pooled standard deviation of
3.6 L × hour. An 0.8 L × hour AUC converts to an average
difference of 67 mL in FEV1 across a 12-hour time period. For
the morning predose/trough FEV1 at the week 13 endpoint,
the contribution of the MF 400 component was expected to
be about 53 mL. This treatment difference can be detected at
a power of 90% with a two-sided alpha level of 5%, assuming
a pooled standard deviation of 230 mL.
Part of the overall effect examination was to compare
the MF/F 200/10 and 400/10 µg doses and identify the possible added benefit of the higher dose of MF/F. Pooling the
studies provided greater precision to the effect of each dose
so such a comparison could be made. Furthermore, pooling
the studies doubled the sample size and increased the power
to detect treatment differences.
An analysis of covariance, extracting sources of variation due to treatment, country, smoking status, and baseline
as covariates, was used to analyze responses for the change
from baseline of the FEV1 AUC0–12 h and the morning predose/
trough FEV1. Pairwise comparisons were based on least
squares means from the model. An analysis of variance,
extracting sources of variation due to treatment, country, and
smoking status, was performed as a confirmatory analysis for
these treatment comparisons. Following testing of the coprimary endpoints at a given dose level of MF/F, tests for the key
secondary endpoints at the given dose level were performed
sequentially versus placebo. Changes from baseline to the
26-week endpoint (last observation carried forward) in SGRQ
total score and the proportion of COPD symptom-free nights,
were analyzed using the same analysis of covariance as specified for the lung function coprimary efficacy variables.

For the time-to-first mild, moderate, or severe COPD
exacerbation, the log-rank test for equality of survival curves
was used with smoking and study as covariates. A GENMOD
model was applied to adjust for smoking and study, and
assumed a negative binomial distribution of events. Kaplan–
Meier curves were used to display these treatment responses.
In addition, the effect of smoking status (current versus former) on the survival curves was examined. Assessments were
repeated for the lower dose (MF/F 200/10 µg). Hazard ratios
were calculated for each active treatment versus placebo on
two endpoint evaluations over 26 weeks, ie, time-to-first mild,
moderate, or severe exacerbation, and time-to-first moderate or
severe exacerbation. However, this required a separate analysis
using the Cox proportional hazards method, which used the
same covariates (smoking and study) as the log-rank test.

Results
Subject disposition and demographics
Of 5249 subjects screened, 2251 were randomized to
treatment. Nine subjects were enrolled at two sites simultaneously and were excluded from analysis. Five subjects
were randomized but did not receive study drug. A total of
1796 subjects completed the treatment period. The primary
reasons for discontinuation were adverse events (4%) and
subjects not wishing to continue for reasons unrelated to the
assigned treatment (5%, Table 1).
Demographic characteristics and baseline lung function are presented in Table 2. Overall, 76% of subjects
were males, 72% were white, and mean age was approximately 60 years. Demographics and disease characteristics
were generally well balanced between treatment arms.
However, the MF/F 400/10 group had a higher smoking

Table 1 Disposition of patients following randomized treatment assignment: number (%) of patients during the treatment period
Subject disposition, n (%)

MF/F 200/10 μg
BID

MF/F 400/10 μg
BID

MF 400 μg
BID

F 10 μg
BID

Placebo
BID

Total

Randomized
Discontinued treatment period
Adverse event
Treatment failure
Lost to follow-up
 Subject did not wish to continue for
reasons unrelated to treatment
 Subject did not wish to continue for
reasons related to treatment
Noncompliance with protocol
Did not meet protocol eligibility
Administrative
Completed treatment period

446
75 (17)
7 (2)
5 (1)
3 (1)
24 (5)

442
75 (17)
21 (5)
4 (1)
3 (1)
11 (2)

463
97 (21)
15 (3)
6 (1)
3 (1)
29 (6)

452
87 (19)
20 (4)
9 (2)
3 (1)
20 (4)

448
120 (27)
21 (5)
16 (4)
6 (1)
28 (6)

2251
454 (20)
84 (4)
40 (2)
18 (1)
112 (5)

6 (1)

7 (2)

13 (3)

11 (2)

16 (4)

53 (2)

10 (2)
14 (3)
6 (1)
371 (83)

8 (2)
15 (3)
6 (1)
366 (83)

7 (2)
20 (4)
4 (1)
366 (79)

11 (2)
9 (2)
4 (1)
365 (81)

10 (2)
19 (4)
4 (1)
328 (73)

46 (2)
77 (3)
24 (1)
1796 (80)

Abbreviations: BID, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.
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Table 2 Summary of demographic data and baseline characteristics
Characteristics

MF/F
200/10 μg
BID
(n = 446)

MF/F
400/10 μg
BID
(n = 442)

MF
400 μg
BID
(n = 463)

F
10 μg
BID
(n = 452)

Placebo
BID
(n = 448)

Total randomized
(n = 2251)

Male, n (%)
Age (years), mean (SD)
Weight (kg), mean (SD)
Race, n (%)
White
Black or African American
Asian
Multiracial
American Indian or Alaskan Native
Smoking status, n (%)
Current smokers
Ex-smokers
Smoking history (pack-years), mean (SD)
FEV1 screening % reversibility, mean (SD)
FEV1 baseline (SD)
FEV1 baseline % predicted (SD)
Prebronchodilator PEF (morning)
baseline, mean (SD)

336 (75)
60.4 (8.6)
71.73 (17.0)

339 (77)
59.4 (9.1)
72.41 (19.4)

361 (78)
60.2 (8.7)
73.31 (18.8)

334 (74)
59.7 (8.6)
71.90 (18.3)

348 (78)
58.8 (9.1)
72.99 (20.3)

1718 (76)
59.7 (8.8)
72.47 (18.8)

322 (72)
11 (2)
73 (16)
39 (9)
1 (,1)

323 (73)
3 (1)
74 (17)
42 (10)
0

336 (73)
6 (1)
78 (17)
43 (9)
0

328 (73)
6 (1)
76 (17)
42 (9)
0

310 (69)
11 (2)
80 (18)
47 (10)
0

1619 (72)
37 (2)
381 (17)
213 (9)
1 (,1)

208 (47)
238 (53)
40.94 (35.2)
8.62 (12.5)
1.21 (0.43)
39.06 (11.6)
186.48 (84.6)

226 (51)
216 (49)
47.39 (134.5)
8.54 (13.2)
1.20 (0.39)
38.14 (10.8)
185.78 (81.0)

226 (49)
235 (51)
40.60 (26.3)
9.09 (14.0)
1.26 (0.44)
40.26 (12.9)
184.99 (77.0)

215 (48)
237 (52)
43.32 (61.3)
9.60 (15.7)
1.22 (0.43)
39.50 (12.1)
182.08 (77.2)

217 (48)
230 (51)
41.95 (40.4)
9.09 (13.9)
1.22 (0.44)
38.55 (11.3)
191.93 (87.5)

1092 (49)
1156 (51)
42.82 (70.8)
8.99 (13.9)
1.22 (0.43)
39.12 (11.8)
186.23 (81.5)

Abbreviations: BID, twice daily; F, formoterol; FEV1, forced expiratory volume in 1 second; MDI, metered-dose inhaler; MF, mometasone furoate; MF/F, mometasone
furoate/formoterol fumarate fixed-dose combination formulation; PEF, peak expiratory flow; SD, standard deviation.

b urden than the other treatment groups (51% current
smokers; 47 pack-years mean smoking history).

Coprimary efficacy outcomes
Improvements in FEV1 AUC0–12 h were significantly greater for
MF/F 400/10 compared with MF 400 (primary comparison;
P , 0.001) and placebo (primary comparison; P , 0.001)
at the week 13 primary endpoint (Figure 2) and all other
endpoints. F 10 was also significantly superior to placebo
(primary comparison) at all endpoints (P  0.008 for all).
These results demonstrate the significant contribution of
formoterol. Improvements in FEV1 AUC0–12 h were also significantly greater for MF/F 200/10 compared with MF 400
and placebo at all time points (P , 0.001 for all). Both doses
of MF/F were significantly superior to F 10 at almost all
endpoints, supporting the contribution of MF to the combination (the difference between MF/F 200/10 and F 10 was not
significant at day 1). Improvements in FEV1 AUC0–12 h were
significantly greater for 400/10 compared with 200/10 at the
week 13 endpoint (P = 0.031) and at 26 weeks (P , 0.05),
demonstrating a dose-response relationship. Changes from
baseline in FEV1 AUC0–12 h are shown as standardized FEV1
values in liters (FEV1 AUC0–12 h divided by 12) in Table 3.

Serial spirometry data
Improvements in AM predose/trough FEV1 were significantly
greater for MF/F 400/10 compared with F 10 (primary
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c omparison; P # 0.008) and placebo (primary comparison;
P , 0.001) at the week 13 primary endpoint and at all other time
points (eg, week 26), supporting the contribution of MF to the
combination (Table 4). No significant difference was observed
between MF 400 and placebo (primary comparison) for change
in morning predose/trough FEV1 at 13 weeks (Figure 3).
The increase in morning predose/trough FEV1 was not
significantly greater with MF/F 200/10 compared with F 10
at the week 13 endpoint. However, MF/F 200/10 was significantly superior to placebo at all endpoints. MF/F 400/10
was significantly superior to MF/F 200/10 at the week 13
endpoint, consistent with the dose-response relationship seen
in the analysis of FEV1 AUC0–12 h. MF/F 400/10 was also
significantly superior to MF 400 at the week 13 endpoint.
No significant improvement was seen when comparing MF/F
200/10 and MF 400 (Figure 4).

Secondary assessments
Baseline mean total SGRQ scores were similar between
groups (range 45.6−47.6). At the week 26 endpoint, all
active treatment arms resulted in a clinically meaningful
improvement in mean total SGRQ score of more than 4 points
(least squares mean changes from baseline were −6.82, −7.08,
−6.54, and −5.71, for MF/F 400/10, MF/F 200/10, MF 400,
and F 10, respectively). These changes were also significantly greater compared with placebo (-3.05, P # 0.007,
Figure 5). The proportion of subjects who achieved minimum
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Change from baseline at
week 13 endpoint in FEV1AUC0–12 h (L × hours)

2.5

2.063* †‡¶
2.0

1.591* †‡
1.5

1.038*
1.0
0.648
0.5
0.123
0.0

MF/F

MF/F

400/10

200/10

MF 400

F 10

Placebo

Figure 2 Change from baseline in FEV1 AUC0–12 h (L × hour) at week 13 (last observation carried forward).
Notes: *P , 0.001 versus placebo; †P , 0.001 versus MF 400; ‡P # 0.011 versus F 10; ¶P = 0.031 versus MF/F 200/10.
Abbreviations: AUC0–12 h, area under the curve from 0 to 12 h postdose; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate;
MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.

assessment included symptoms over the week prior to the first
dose of study medication. The proportion of COPD symptomfree nights over the 26-week treatment period increased in
all treatment groups, with a least squares mean change from
baseline of 0.15, 0.13, 0.14, 0.14, and 0.10 in the MF/F
400/10, MF/F 200/10, MF 400, F 10, and placebo groups,
respectively. Compared with placebo, significantly greater
improvements were seen in the MF/F 400/10, MF 400, and
F 10 arms (P # 0.033) but not in the MF/F 200/10 arm.

c linically important difference changes from baseline
of at least 4 points in SGRQ scores in the MF/F 400/10,
MF/F 200/10, MF 400, F 10, and placebo groups was 52%
(218/418), 53% (223/423), 53% (229/433), 51% (218/432),
and 42% (173/414). The differences between proportions
in all active treatment groups and the placebo group were
statistically significant (P # 0.011).
The proportion of COPD symptom-free nights was similar between groups at baseline (range 0.25−0.29); baseline

Table 3 Change from baseline in FEV1 AUC0–12 h in all randomized subjects

Change from BL
Day 1
Week 1
Week 13
Week 13 EPb
Week 26
Week 26 EPb

MF/F 200/10 μg BID

MF/F 400/10 μg BID

MF 400 μg BID

F 10 μg BID

Placebo

n

LS mean

n

LS mean

n

LS mean

n

LS mean

n

LS mean

434
408
388
437
336
438

1.452*,†
1.836*,†,‡
1.621*,†,‡
1.591*,†,‡
1.365*,†,‡
1.376*,†,‡

426
401
374
430
330
430

1.553*,†,‡
1.936*,†,‡
2.218*,†,‡
2.063*,†,‡
1.879*,†,‡
1.809*,†,‡

444
413
392
453
335
454

0.189
0.641*
0.556*
0.648*
0.316
0.513*

437
422
377
444
331
444

1.197*,†
1.281*,†
1.070*,†
1.038*
0.713*
0.790*

421
389
346
432
281
432

0.024
0.049
-0.006
0.123
-0.010
0.040

a

Notes: aLS means are obtained from an analysis of covariance model with treatment, strata (ex-smoker or current smoker), country and study as factors and baseline
as a covariate; blast post-baseline non-missing result through the 13-week or 26-week evaluation carried forward. *P , 0.032 versus placebo; †P , 0.029 versus MF 400;
‡
P , 0.05 versus F 10.
Abbreviations: BID, twice daily; BL, baseline; EP, endpoint; F, formoterol; FEV1, forced expiratory volume in 1 second; LS, least squares; MF, mometasone furoate;
MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.
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Table 4 Change from baseline in morning predose/trough FEV1 in all randomized subjects

Change from BL
Week 1
Week 4
Week 13
Week 13 EPb
Week 26
Week 26 EPb

MF/F 200/10 μg BID

MF/F 400/10 μg BID

MF 400 μg BID

F 10 μg BID

Placebo

n

LS mean

n

LS mean

n

LS mean

n

LS mean

n

LS mean

412
418
408
431
352
431

0.061*,†,‡
0.075*
0.061*
0.060*
0.063*,‡
0.065*,‡

417
409
396
428
342
428

0.070*,†,‡
0.091*,†,‡
0.112*,†,‡,§
0.104*,†,‡,§
0.102*,†,‡
0.090*,†,‡

435
434
412
451
347
451

0.011*
0.054*
0.025*
0.026
0.031*
0.036*

434
418
399
443
341
443

0.027*
0.043
0.025*
0.026

413
407
378
428
310
428

-0.020
0.019
-0.025
-0.010
-0.018
-0.004

a

-0.002
0.008

Notes: aLeast squares means are obtained from an analysis of covariance model with treatment, smoking strata (ex-smoker or current smoker), country, and study as factors
in addition to baseline as a covariate; blast post-baseline non-missing result through the 13-week or 26-week evaluation carried forward. *P , 0.05 versus placebo; †P # 0.039
versus MF 400; ‡P # 0.025 versus F 10; §P , 0.02 versus MF/F 200/10.
Abbreviations: AM, morning; BID, twice daily; BL, baseline; EP, endpoint; F, formoterol; FEV1, forced expiratory volume in 1 second; LS, least squares; MF, mometasone
furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.

In the evaluation of pooled data for subjects with partly
stable COPD over the last 8 weeks of treatment, no statistically significant differences were observed between treatments at the week 26 endpoint for the proportion of subjects
with partly stable COPD. In the MF/F 400/10, MF/F 200/10,
MF 400, F 10, and placebo groups, the proportions of subjects
with partly stable COPD at endpoint were 39.5%, 44.3%,
38.1%, 42.0%, and 38.7%, respectively.

COPD exacerbations
The percentage of subjects who experienced at least one mild,
moderate, or severe COPD exacerbation across the 26-week

treatment period in the MF/F 400/10, MF/F 200/10, MF 400,
F 10, and placebo groups were 31.7%, 33.3%, 33.8%, 39.1%,
and 39.4%, respectively. Based on the log-rank test for equality
of survival curves (adjusted for smoking), MF/F 400/10, MF/F
200/10, and MF 400 were superior to placebo (P # 0.038).
MF/F 400/10 and MF/F 200/10 were also superior to F 10
(P # 0.049, Figure 6). When only moderate and severe exacerbations were considered, the combination arms separated
more distinctly from the other treatment arms. The percentage
of subjects with moderate or severe COPD exacerbations was
12.1% with MF/F 400/10 and 20.7% with placebo. Based
on adjusted survival curves, MF/F 400/10 was superior to

endpoint in AM predose FEV1 (mL)

Change from baseline to week 13

120

*†‡¶

104
100
80

60*
60

40
26

26

MF 400

F 10

20
0
−20

−10

MF/F

MF/F

400/10

200/10

Placebo

Figure 3 Morning predose/trough FEV1 at week 13 endpoint (last observation carried forward).
Notes: *P , 0.001 versus placebo; †P , 0.001 versus MF 400; ‡P , 0.001 versus F 10; ¶P = 0.018 versus MF/F 200/10.
Abbreviations: FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose
combination formulation.
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Change from baseline in AM
predose (trough) FEV1 (mL)

120
100
80
60
40
20
0
−20
−40

Week 1

Week 4

Week 13

Week 26

MF/F 400/10
MF 400
Placebo

Week 39

Week 52

MF/F 200/10
F 10

Figure 4 Changes from baseline in morning predose/trough FEV1 over the study period (last observation carried forward).
Note: Subjects randomized to placebo were only enrolled up to week 26.
Abbreviations: F, formoterol; FEV1, forced expiratory volume in 1 second; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination
formulation.

MF 400, F 10, and placebo (P # 0.030); MF/F 200/10 was
superior only to F 10 and placebo (P # 0.009).
Pooled exposure-adjusted exacerbation rates showed
that the incidence of exacerbations was lower in the MF/F
and MF groups than it was in the formoterol group over the
52-week study period. The calculation of exposure-adjusted

MF/F 400/10

MF/F 200/10

rates, expressed as events per patient-years, adjusts for the
varying duration of exposure across treatments. The pooled
exacerbation rates for the MF/F 400/10, MF/F 200/10, MF
400, and F 10 groups over the study period were 0.33, 0.34,
0.35, and 0.42 patient-years, respectively. Treatment advantages were marginally significant for MF/F 400/10 versus

MF 400

F 10

Placebo

0

Change from baseline in
SGRQ total score

−1
−2
−3
−3.05
−4
−5
−6
−7

−5.71 †
−6.82*

−6.54*
−7.08*

−8
Figure 5 St George’s Respiratory Questionnaire total score change from baseline at week 26 endpoint.
Notes: *P , 0.001 versus placebo; †P = 0.007 versus placebo.
Abbreviations: F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation; SGRQ, St George’s
Respiratory Questionnaire.
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1.0

Probability of no COPD exacerbation

0.9

0.8

0.7

0.6

0.5

0.4
20

0
Treatment

40
MFF 200/10

60

80

100
120
Days in the study

MFF 400/10

MF 400

140
F 10

160

180

200

Placebo

Figure 6 Time-to-first mild, moderate or severe COPD exacerbation over the 26-week treatment period: Kaplan–Meier survival curves by treatment (all randomized subjects).
Abbreviations: F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.

F 10 (P = 0.052) and MF/F 200/10 versus F 10 (P = 0.063)
adjusting for smoking and study.
Using the Cox proportional hazard model, pooled hazard
ratios for mild, moderate, or severe exacerbations with MF/F
400/10, MF/F 200/10, MF 400, and F 10 versus placebo were
0.761, 0.782, 0.825, and 0.972, respectively. The pooled
hazard ratios for moderate or severe exacerbations with MF/F
400/10, MF/F 200/10, MF 400, and F 10 versus placebo were
0.571, 0.611, 0.828, and 0.957, respectively.

Safety
All four active treatments were well tolerated. During
the 26-week treatment period, the percentage of subjects
reporting any treatment-emergent adverse event was
similar across the five treatment groups (31.8% with
MF/F 200/10 to 36.2% with placebo). The most commonly reported treatment-emergent adverse events were
headache, COPD, nasopharyngitis, upper respiratory tract
infection, and hypertension (Table 5). COPD was reported
as an adverse event if the subject had COPD symptoms
or an exacerbation the investigator judged to have a clear
temporal relationship with treatment administration. The
incidence of COPD as a treatment-emergent adverse event
was reported by 63 subjects (2.8%), ranging from 1.6%
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in the MF/F 200/10 group to 4.2% in the placebo group.
During the treatment period, 164 subjects reported serious
adverse events. COPD was by far the most frequent severe
adverse event, reported by 15, 7, 12, 12, and 20 subjects in
the MF/F 400/10, MF/F 200/10, MF 400, F 10, and placebo
groups, respectively. Pooled results for treatment-emergent
adverse events over the 52-week study period demonstrated
that 17.0%–19.0% of subjects across the active treatment
groups reported mild adverse events, whereas 15.4%–17.7%
of subjects reported moderate adverse events. No more than
7.0% of subjects in any group reported severe treatmentemergent adverse events.
Treatment-related oral candidiasis, including esophageal
and oropharyngeal, was reported by 19 subjects overall
(0.8%) during the treatment period. Pneumonia, including
lobar and viral pneumonia, was infrequent, occurring in
nine (2.0%), five (1.1%), five (1.1%), six (1.3%), and three
(0.7%) subjects in the MF/F 400/10, MF/F 200/10, MF 400,
F 10, and placebo groups. During the 52-week study period,
fewer than 6% of subjects in any treatment group reported
any single treatment-emergent adverse event of any severity.
Across the treatment groups, more subjects reported mild
treatment-emergent adverse events than treatment-emergent
adverse events of greater severity.
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Table 5 Summary of treatment-emergent adverse events $2% incidence (all randomized subjects) during the treatment period
Adverse events,
n (%)

MF/F 200/10 μg BID
(n = 446)

MF/F 400/10 μg BID
(n = 442)

MF 400 μg BID
(n = 463)

F 10 μg BID
(n = 452)

Placebo
(n = 448)

Patients reporting any adverse
event, n (%)
Nasopharyngitis
Influenza
Upper respiratory tract infection
Headache
Chronic obstructive pulmonary
diseasea
Hypertension
Back pain

142 (31.8)

157 (35.5)

156 (33.7)

163 (36.1)

162 (36.2)

9 (2.0)
10 (2.2)
9 (2.0)
15 (3.4)
7 (1.6)

13 (2.9)
4 (0.9)
16 (3.6)
13 (2.9)
15 (3.4)

14 (3.0)
9 (1.9)
10 (2.2)
17 (3.7)
11 (2.4)

12 (2.7)
8 (1.8)
8 (1.8)
19 (4.2)
11 (2.4)

12 (2.7)
7 (1.6)
16 (3.6)
22 (4.9)
19 (4.2)

15 (3.4)
6 (1.3)

7 (1.6)
3 (0.7)

8 (1.7)
6 (1.3)

13 (2.9)
9 (2.0)

8 (1.8)
5 (1.1)

Note: aIf COPD exacerbation met criteria for a severe adverse event (eg, life-threatening, required hospitalization or prolonged hospitalization) it was recorded as an
adverse event.
Abbreviations: BID, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fumarate fixed-dose combination formulation.

No abnormal, clinically relevant trends in laboratory
values, vital signs, or electrocardiogram measurements
were observed in the two studies. No clinically relevant
trends or statistically significant treatment differences were
observed for plasma cortisol levels, bone mineral density
measurements, ocular changes, or forearm bruising.

Discussion
In this prospectively designed pooled analysis of two large,
placebo-controlled Phase III studies in subjects with moderate
to very severe COPD, significantly greater improvements in
lung function were seen for twice-daily treatment using MF/F
compared with placebo. Both dosing levels (MF/F 400/10 and
MF/F 200/10) demonstrated significant improvements in both
coprimary efficacy variables (morning predose/trough FEV1
and FEV1 AUC0–12 h) compared with placebo at all assessments
from day 1 through week 26. In comparing the two combination regimens, the higher dose was associated with statistically
greater improvements in both coprimary endpoints, demonstrating a significant dose-response relationship. Significant
benefits in health status, night-time symptoms, and COPD
exacerbation rates were also demonstrated with both MF/F
doses. Both MF/F doses were well tolerated relative to their
individual components and placebo.

Contribution of individual components
Although inhaled corticosteroids are frequently prescribed
to reduce symptoms, improve health status, and decrease
exacerbations,25 inhaled corticosteroid monotherapy is not
recommended in COPD treatment guidelines1 and is also not
approved for treatment of COPD in the US.25 However, MF
has been shown to improve lung function and health status
and reduce exacerbations significantly over 1 year.13

International Journal of COPD 2012:7

Our results show that MF contributes to the efficacy of
MF/F, as demonstrated by significantly greater improvement in morning predose/trough FEV1 with MF/F 400/10
compared with F 10. These differences were significant at
day 1 and continued through 26 weeks. Improvements were
not significantly different between inhaled corticosteroid
monotherapy, MF 400, and placebo at the week 13 primary
endpoint, but were significant at all other endpoints. Likewise, significantly greater improvements in FEV1 AUC0–12 h
for MF/F 200/10 and 400/10 compared with F 10 across all
time points from week 1 through week 26 demonstrate the
contribution of MF to the combination.
LABAs are recommended for long-term management of
COPD, and patients treated with formoterol, an approved
COPD monotherapy in the US, demonstrate rapid onset of
bronchodilation and sustained improvements in lung function
with twice-daily dosing.4,26,27 Our results show that formoterol contributes to the efficacy of combination therapy, as
demonstrated by the significantly greater improvement in
FEV1 AUC0–12 h with MF/F 400/10 compared with MF 400.
Improvements in FEV1 AUC0–12 h were also significantly
greater with F 10 than with placebo.
Health status, assessed using the SGRQ, was significantly improved with both combination doses. SGRQ has
been widely utilized to assess health status in inhaled
corticosteroid-LABA combination trials.11,18,19,28–30 In studies
up to 1 year, a change from baseline of more than 4 points
has been reported with some combination regimens18,19 but
not others.18,19,29 Rennard et al and Tashkin et al compared
budesonide/formoterol 160/9 µg twice daily with budesonide/formoterol 320/9 µg twice daily. In both studies, the
change from baseline was .4 points in the lower-dose groups
but ,4 points in the higher-dose groups. In the current
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analysis, both MF/F doses resulted in clinically relevant
improvements (.4 point change from baseline); however, the
lower-dose group additionally demonstrated a change of .4
points compared with placebo. Effects such as these were not
seen with higher-dose and lower-dose combinations in other
studies,11,18,19,28–30 which did not evaluate MF/F. MF/F 400/10
also demonstrated a significant improvement over placebo
in the proportion of COPD symptom-free nights; however,
the lower-dose combination did not show a significant difference over placebo.
The primary modes of action of LABAs and inhaled corticosteroids are distinct, namely bronchodilation and suppression
of airway inflammation.31 However, the following potential
synergistic effects between the two classes have been suggested
based on in vitro studies: inhaled corticosteroids enhance
β2-adrenoceptor expression, which may prevent development
of tolerance to β2-agonists with prolonged use; and LABAs
amplify the anti-inflammatory effects of corticosteroids by
accelerating nuclear translocation of the glucocorticoid receptor
complex and enhancing transcription and expression of steroidinducible genes in proinflammatory cells.32,33 Our analysis
supports a synergistic effect of mometasone and formoterol
on lung function. Based on morning predose/trough FEV1
measurements, MF/F 400/10 had a treatment effect (change
from baseline) of 104 mL at the primary endpoint (13 weeks),
which was greater than the summed treatment effects of MF and
F (26 mL and 26 mL, respectively). Similarly, for standardized
FEV1 AUC0–12 h, the treatment effect of MF/F 400/10 (172 mL)
was greater than the sum of the treatment effects of MF 400
and F 10 (87 mL and 54 mL, respectively).
Although these trials were not designed to compare the
efficacy of the two MF/F combination doses, the results
clearly suggest greater benefits with MF/F 400/10 than with
MF/F 200/10. Improvements in lung function (morning
predose/trough FEV1 and FEV1 AUC0–12 h) were significantly
greater with MF/F 400/10 compared with MF/F 200/10 at
the week 13 endpoint, and were numerically greater at all
assessment times.
Dose-dependent responses were also seen in the percentage of subjects who developed exacerbations of COPD symptoms and in reductions in night-time symptoms, although the
differences between the higher-dose and lower-dose groups
were not statistically significant.
Pooled exposure-adjusted exacerbation rates were lower
in the MF/F groups than they were in the formoterol group,
although the differences were marginally significant. In
addition, compared with placebo, pooled hazard ratios
for mild, moderate, or severe exacerbations were reduced
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19% more in the MF/F 200/10 group and 21% more in
the MF/F 400/10 group than they were in the formoterol
group. Furthermore, pooled hazard ratios for moderate or
severe exacerbations were reduced 35% more in the MF/F
200/10 group and 39% more in the MF/F 400/10 group than
they were in the formoterol group.

Safety
MF/F was well tolerated at both dosing levels. The
occurrence of total adverse events and treatment-related
adverse events was similar across active treatment groups.
A dose-related increase in the risk of pneumonia has been
associated with the use of inhaled corticosteroid-containing
regimens in COPD patients.34,35 We found that the incidence
of pneumonia was low overall, although slightly higher in
the MF/F 400/10 group than in other groups. Other studies
have also reported an increase in oral candidiasis in inhaled
corticosteroid-LABA trials.16,18 Oral candidiasis was very
infrequent, with similar rates seen in the combination
arms compared with non-MF-containing arms (F 10 and
placebo). There was also an absence of any significant
demonstrable adverse effect on bone density or ocular
changes. While these data indicate MF/F was safe over
the course of 1 year, longer trials should be conducted to
confirm long-term safety.

Conclusion
In this pooled analysis of two large, 1-year, placebocontrolled clinical trials, patients treated with the MF/F
pressurized metered-dose inhaler combination demonstrated
significant improvements in lung function, health status, and
exacerbation rates at the two doses investigated. Although
significant improvements were seen at both combination
doses, the higher dose was significantly more effective
in improving lung function. A dose-response effect was
observed in the lung function measurements.
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